@prefix jvr: <http://data.loterre.fr/ark:/67375/JVR> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .

jvr:-BT300B3G-Q
  skos:prefLabel "cerebrospinal fluid (Qualifier)"@en, "liquide cérébrospinal (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-G3J703SV-B
  skos:prefLabel "Antilépreux"@fr, "Leprostatic Agents"@en ;
  a mesh:Descriptor, skos:Concept .

jvr:-L6C0XPHT-4
  skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-XV06LPML-W
  skos:prefLabel "urine (Qualifier)"@en, "urine (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-Q3979798-W
  skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-H7K65Q8S-Z
  skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TJHVZCRZ-0
  skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-G30ZJ446-J
  skos:prefLabel "toxicity (Qualifier)"@en, "toxicité (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NFTHND7Q-8
  skos:prefLabel "intoxication (Qualificatif)"@fr, "poisoning (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-FWD2BGQ0-9
  skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-THHNVC7V-3
  skos:prefLabel "synthèse chimique (Qualificatif)"@fr, "chemical synthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-R0ZCQ8X6-J
  skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-M63HSDM7-1
  skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-S0CS1X5R-5
  skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-HQRFT0C6-B
  skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-NB0XHT3S-N
  skos:prefLabel "adverse effects (Qualifier)"@en, "effets indésirables (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-W6SQV79N-S
  skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CB30NGKB-3
  skos:prefLabel "economics (Qualifier)"@en, "économie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-XM37ZFVC-V
  skos:hiddenLabel "G-30,320"@en, "Lamprene"@en, "B-663"@en ;
  skos:prefLabel "Clofazimine"@en, "Clofazimine"@fr ;
  skos:altLabel "2030-63-9 (Clofazimine)"@fr, "2030-63-9 (Clofazimine)"@en, "2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-"@fr, "2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-"@en, "N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine"@en, "D959AE5USF"@en, "D959AE5USF"@fr ;
  mesh:allowableQualifier jvr:-G30ZJ446-J, jvr:-R3QWLHRG-V, jvr:-L6C0XPHT-4, jvr:-SBNWSM1T-R, jvr:-XV06LPML-W, jvr:-W6SQV79N-S, jvr:-G4R176S9-J, jvr:-FWD2BGQ0-9, jvr:-H7K65Q8S-Z, jvr:-WK5F724J-1, jvr:-NB0XHT3S-N, jvr:-NKM836P1-M, jvr:-M63HSDM7-1, jvr:-NFTHND7Q-8, jvr:-Q3979798-W, jvr:-TJHVZCRZ-0, jvr:-THHNVC7V-3, jvr:-S0CS1X5R-5, jvr:-R0ZCQ8X6-J, jvr:-T9HQD7ST-J, jvr:-NHL3D2X0-S, jvr:-CB30NGKB-3, jvr:-D0F21513-5, jvr:-BT300B3G-Q, jvr:-HQRFT0C6-B ;
  a mesh:Descriptor, skos:Concept ;
  skos:definition "A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)"@en ;
  mesh:pharmacologicalAction jvr:-G3J703SV-B, jvr:-FW3F2V3X-Z ;
  skos:broader jvr:-JWSCWCDX-5 ;
  dc:established "1974-01-01"^^xsd:date ;
  dc:created "1999-01-01"^^xsd:date ;
  owl:sameAs <http://id.nlm.nih.gov/mesh/D002991> ;
  dc:modified "2016-05-28"^^xsd:date ;
  skos:inScheme jvr: .

jvr:-G4R176S9-J
  skos:prefLabel "analogs & derivatives (Qualifier)"@en, "analogues et dérivés (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr: a skos:ConceptScheme .
jvr:-SBNWSM1T-R
  skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-D0F21513-5
  skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-R3QWLHRG-V
  skos:prefLabel "standards (Qualifier)"@en, "normes (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-JWSCWCDX-5
  skos:prefLabel "Phénazines"@fr, "Phenazines"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-XM37ZFVC-V .

jvr:-NHL3D2X0-S
  skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-T9HQD7ST-J
  skos:prefLabel "ressources et distribution (Qualificatif)"@fr, "supply & distribution (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-NKM836P1-M
  skos:prefLabel "pharmacology (Qualifier)"@en, "pharmacologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-FW3F2V3X-Z
  skos:prefLabel "Anti-inflammatoires"@fr, "Anti-Inflammatory Agents"@en ;
  a mesh:Descriptor, skos:Concept .

jvr:-WK5F724J-1
  skos:prefLabel "pharmacokinetics (Qualifier)"@en, "pharmacocinétique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .